Sucrosofate (potassium)

O=S(OC[C@@]1([C@H]([C@@H]([C@H](O1)COS(=O)(O[K])=O)OS(=O)(O[K])=O)OS(=O)(O[K])=O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(O[K])=O)OS(=O)(O[K])=O)OS(=O)(O[K])=O)OS(=O)(O[K])=O)(O[K])=O

[1]Ko A H, Tempero M A, Shan Y S, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer[J]. British journal of cancer, 2013, 109 (4) : 920-925.|[2]Klinz S G, Zheng J, De Souza R, et al. Abstract C293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F] FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model[J]. Molecular Cancer Therapeutics, 2013, 12 (11_Supplement) : C293-C293.